Svetlana Nikic, Founder of Precision Oncology Consulting, shared a post on LinkedIn by Foundation Medicine, adding:
“And there’s another me-too product out there – Foundation Medicine launches their WGS whole-genome based MRD assay – FlexOMx Lab.
FlexOMx Lab joins the growing set of genome-informed MRD offerings, including:
- Myriad Genetics’s Precise MRD (tumor-informed, WGS-based)
- Natera’s Signatera Genome assay
- Labcorp’s Plasma Detect,
- Personalis, Inc.’ NeXTPersonal
- Veracyte, Inc.’s MRDetect
- Illumina’s TSO MRD WGS
Maybe I’m wrong but I don’t think it’s the sensitivity of these different assays that’ll make a difference, but rather IMPLEMENTABILITY… and where is Roche in this WGS-based MRD space 🙂 by the way?”
Quoting Foundation Medicine’s post:
“Excited to share the launch of our new tissue-informed whole genome sequencing molecular residual disease (Tissue-informed WGS MRD) test for research use in early to late-stage cancers through our FlexOMx Lab.
More from Svetlana Nikic on OncoDaily.